on BIOSYNEX (EPA:ALBIO)
BIOSYNEX SA: 2024 Results and 2025 Reorganization Plan
BIOSYNEX SA announced its annual results for 2024, showing a 9% increase in revenue, driven by improved export performance. Gross margin increased by 16% thanks to an improved product mix. Despite costs related to the disposal of obsolete inventory and acquisitions, the operating loss was reduced by 3%.
The company is continuing its reorganization in 2025, targeting cost synergies through the streamlining of its international sites. In the first quarter of 2025, revenue grew 2% compared to the previous year.
The debt restructuring plan, underway since 2024, has strengthened the group's financial structure, despite persistent uncertainty regarding the achievement of its future objectives.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOSYNEX news